AUTHORS
Bing Li, MD, Jian Huang2, Min Zhang3, Jie Bai4, Xuliang Shen, MD5, Hu Zhou, MD6, Yu Yan, MD7, Junqing Xu8, Jieyu Wang, MD9, Lifang Huang10, Rong Gong11, Zhitian Hu12, Ning Wang13, Fang Tian14, Jianchi Ma15, Cong Ma16, Yinhan Guo17, Gang Huang, MD18, Zhijian Xiao19
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 The First Affiliated Hospital ,Zhejiang University School of Medicine, Hangzhou, China
3 Institute of Hematology, Union Hospital, Tongji Medical College, HUST, Wuhan, China
4 The Second Hospital of Tianjin Medical University, Tianjin, China
5 Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China
6 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
7 North China University of Science and Technology Affiliated Hospital, Tangshan, China
8 Yantai Yuhuangding Hospital, Yantai, China
9 Jiangxi Provincial Key Laboratory of Hematological Diseases, Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
10 Shanxi Bethune Hospital, Taiyuan, China
11 Shanxi Bethune Hospital, Taiyuan, China
12 Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China
13 Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China
14 Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China
15 Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China
16 Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China
17 Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China
18 MD Anderson Mays Cancer Center at UT Health San Antonio, San Antonio, United States
19 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Background
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by uncontrolled erythrocytosis and thrombotic risks due to inadequate hematocrit (HCT) control. While guidelines recommend HCT <45%, real-world data (REVEAL; Grunwald et al, 2019) show that 57.1% of hydroxyurea (HU)-treated patients experience HCT elevations >45%, and 37.1% discontinue HU due to intolerance, highlighting an unmet need for alternative therapies.9MW3011 is a novel humanized monoclonal antibody targeting transmembrane serine protease 6 (TMPRSS6), which modulates the BMP/SMAD–hepcidin pathway to inhibit erythropoiesis. Herein, we present results from the phase Ib study (NCT06752746) evaluating the safety and tolerability of multiple intravenous administrations of 9MW3011 in Chinese PV patients, and further assessing its therapeutic effects and pharmacodynamic (PD) characteristics.
Methods
In stage 1 (initial dose period), 25 eligible participants (pts) were randomized 1:1:1 to the 150 mg Q4W, 150 mg Q2W, or 300 mg Q4W groups. In stage 2 (dose-escalation period), 24 eligible pts were enrolled into the 600 mg Q4W and 900 mg Q4W groups. All treatment consisted of 5 cycles of dosing. Safety events, iron metabolism PD markers (hepcidin, serum iron and ferritin), and efficacy-related parameters (e.g., HCT) were assessed throughout the study. Efficacy was further evaluated based on the rates of cytoreductive-therapy-free (CTF) status. CTF is considered as the absence of cytoreductive intervention such as HU and interferon-alpha (IFN-α). The need for intervention was determined according to baseline HCT levels: for pts with baseline HCT<45%, post-treatment HCT ≥45% (with ≥3% increase) or ≥48%; for pts with baseline HCT ≥45%, an HCT increase ≥3%.
Results
As of June 5, 2026, a total of 39 pts had completed 5 cycles of dosing and at least 2 weeks of safety follow-up: 21 in the initial dose period (150 mg Q4W, n=6; 150 mg Q2W, n=8; 300 mg Q4W, n=7) and 18 in the dose-escalation period (600 mg Q4W, n=11; 900 mg Q4W, n=7). Among these 39 pts (28 males and 11 females), the median age was 56 years; 27 (69.2%) were Relapsed/Refractory (resistant or intolerant to HU or IFN-α). The mean baseline HCT levels were 54.1%, 47.7%, 53.0%, 55.2%, and 54.0%, in the 150 mg Q4W, 150 mg Q2W, 300 mg Q4W, 600 mg Q4W and 900 mg Q4W groups, respectively.9MW3011 exhibited preliminary efficacy signals of decreased dependence on cytoreductive therapy. With more pts evaluable at longer follow-up, the assessment time point set at 2 weeks after the last dose (127 days for Q4W and 71 days for Q2W). Rates of pts remaining CTF were 33%, 75%, 86%, 64% and 71%, respectively, with the highest rate observed in the 300 mg Q4W group. Preliminary efficacy signals were further supported by PD markers of iron metabolism. Following 9MW3011 administration, a dose-dependent increase in the percentage change from baseline of hepcidin levels was observed, reflecting a robust PD effect in promoting endogenous hepcidin expression. Serum iron levels declined rapidly and stabilized below baseline. Notably, ferritin elevation and HCT reduction demonstrated a significant, time-dependent negative correlation, indicating the effect of 9MW3011 on iron-restriction and highlighting the therapeutic potential for PV management. Overall, 9MW3011 was safe and well tolerated across all dose levels. The majority adverse events (AEs) were grade 1-2 (94.5% of all AEs), only 5.5% were Grade ≥3. The most common AEs were laboratory abnormalities (57.1%, n=28/49), such as elevations in ALT and AST, which were mostly reversible or resolved. Decreased serum iron (Grade 1) was observed; however, no iron deficiency anemia occurred. No deaths or serious adverse reactions were reported. No clinically significant safety risk signals were identified.
Conclusions
The current results indicate that 9MW3011 is a safe and effective iron-restricting agent for controlling HCT in PV patients, reducing dependency on cytoreductive therapies and potentially reducing associated adverse reaction burdens while improving quality of life. Eligible pts could enter an extension phase to further evaluate long-term safety and efficacy.
Corresponding Author: Zhijian Xiao, zjxiao@ihcams.ac.cn; Bing Li, libing@ihcams.ac.cn.
DISCLOSURES
Bing Li, MD: Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China - Research Funding